Vytrus Biotech, S.A. Share Price

Equities

VYT

ES0105618005

Environmental Services & Equipment

Market Closed - BME 15:00:11 08/05/2024 BST 5-day change 1st Jan Change
2.4 EUR +1.69% Intraday chart for Vytrus Biotech, S.A. +1.69% +29.03%

Financials

Sales 2024 * 4.58M 4.92M 394M Sales 2025 * - Capitalization 16.16M 17.37M 1.39B
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 3.76 x
Net Debt 2024 * 1.03M 1.11M 88.85M Net cash position 2025 * - 0 0 EV / Sales 2025 * -
P/E ratio 2024 *
21.8 x
P/E ratio 2025 *
-
Employees 35
Yield 2024 *
-
Yield 2025 *
-
Free-Float 31.36%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.69%
1 week+1.69%
Current month+1.69%
1 month+7.14%
3 months+16.50%
6 months+13.21%
Current year+29.03%
More quotes
1 week
2.30
Extreme 2.3
2.40
1 month
2.24
Extreme 2.24
2.50
Current year
1.84
Extreme 1.84
2.50
1 year
1.78
Extreme 1.78
3.08
3 years
1.78
Extreme 1.78
4.00
5 years
1.78
Extreme 1.78
4.00
10 years
1.78
Extreme 1.78
4.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 31/12/08
Chief Executive Officer - 31/12/08
Director of Finance/CFO - -
Members of the board TitleAgeSince
Chief Executive Officer - 31/12/08
Chief Executive Officer - 31/12/08
Director/Board Member - -
More insiders
Date Price Change Volume
08/05/24 2.4 +1.69% 2,462
07/05/24 2.36 0.00% 0
06/05/24 2.36 0.00% 0
03/05/24 2.36 0.00% 36
02/05/24 2.36 0.00% 9,000

Delayed Quote BME, May 08, 2024 at 03:00 pm

More quotes
Vytrus Biotech SA, formerly Phyture Biotech SL, is Spain-based company principally engaged in the biotechnology industry. The Company develops high added value natural active ingredients on an industrial scale and provides ingredients and recombinant proteins for its use in the cosmetics and pharmaceutical sectors. The Company’s technology is based on using plant cell cultures to produce bioactive molecules. The Company obtains plant cells, known as Plant Stem Cell technology, which is applicable for cosmetics. Vytrus Biotech specifically target dermo-cosmetics as well as veterinary medicine, functional food and other pharmaceuticals, generating savings of more than 99% in natural resources.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.4 EUR
Average target price
3.28 EUR
Spread / Average Target
+36.67%
Consensus

Annual profits - Rate of surprise